文献速递类风湿关节炎

类风湿关节炎患者治疗满意度的相关因素:来自生物制剂登记研究RABBIT的数据

Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT.
PubMed 文献 · RMD Open · 2020-01-01

基于RABBIT登记研究10 646例类风湿关节炎患者,评估开始bDMARD、tsDMARD或csDMARD治疗后1年的治疗满意度。结果显示85%对疗效满意、90%对耐受性满意;基线满意度、血清阳性、DAS28下降、疼痛减轻和体能改善与满意度正相关,而糖皮质激素>5 mg/天、抑郁、纤维肌痛、肥胖、既往bDMARD和换药负相关;激素减量 positively 关联满意度改善。

要点

  • 治疗1年后85%满意疗效、90%满意耐受性。
  • 基线满意度、血清阳性、DAS28和疼痛改善与满意度正相关。
  • 激素>5 mg/天、抑郁、纤维肌痛、肥胖、既往bDMARD和换药负相关。

核心结论

  • 大多数患者治疗1年后对疗效和耐受性满意。
  • 糖皮质激素减量 positively 关联患者满意度改善。

研究设计与样本

  • RABBIT登记研究中开始bDMARD、tsDMARD或csDMARD治疗且既往≥1种csDMARD失败的患者。
  • 治疗1年后测量四类治疗满意度并二分类分析,采用逻辑回归计算相关因素OR。

主要发现

  • 分析10 646例患者(74%女性,平均58岁);基线55%满意疗效、68%满意耐受性。
  • 1年后85%满意疗效、90%满意耐受性。
  • 基线满意度OR 2.98(95%CI 2.58-3.44)、血清阳性OR 1.36(95%CI 1.17-1.57)、DAS28下降OR 1.38(95%CI 1.31-1.46)、疼痛减轻OR 1.26(95%CI 1.22-1.31)、体能改善OR 1.22(95%CI 1.17-1.29)与随访满意度正相关。
  • GC>15 mg/天OR 0.24(95%CI 0.16-0.34),GC影响呈剂量依赖;12个月内减量5 mg/天与疗效满意度OR 1.19(95%CI 1.11-1.27)和耐受性满意度OR 1.11(95%CI 1.03-1.21)正相关。

临床怎么用

  • 临床中应关注激素剂量,>5 mg/天与满意度负相关,>15 mg/天负相关最强。
  • 控制疾病活动、减轻疼痛和改善体能可能提升治疗满意度。
  • 合并抑郁、纤维肌痛、肥胖及既往bDMARD失败或换药者满意度可能较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess satisfaction with the effectiveness and tolerability of treatments in patients with rheumatoid arthritis (RA). METHODS: Patients from the RABBIT register, starting a biological (b) or targeted synthetic (ts) disease-modifying antirheumatic drug (DMARD), or a conventional synthetic (cs)DMARD treatment after ≥1 csDMARD failure, were included. Treatment satisfaction was measured after 1 year of treatment in four categories and binarised for analysis. Logistic regression models were performed to calculate ORs for factors associated with treatment satisfaction. RESULTS: Data of 10 646 patients (74% women, mean 58 years) were analysed. At baseline, 55% of the patients were satisfied with the efficacy and 68% with the tolerability of their previously given treatments. After 1 year, 85% of the patients were satisfied with treatment effectiveness and 90% with tolerability. Baseline satisfaction (OR 2.98, 95% CI 2.58 to 3.44), seropositivity (OR 1.36, 95% CI 1.17 to 1.57), reduction of DAS28 (OR 1.38, 95% CI 1.31 to 1.46) and pain (OR 1.26, 95% CI 1.22 to 1.31), and the improvement of physical capacity (OR 1.22, 95% CI 1.17 to 1.29) were positively associated with treatment satisfaction at follow-up while glucocorticoids (GCs) >5 mg/day, depression, fibromyalgia, obesity, prior bDMARDs and therapy changes were negatively associated. The impact of GC on satisfaction was dose-dependent, becoming strongest for GC >15 mg (OR 0.24, 95% CI 0.16 to 0.34). A 5 mg/day reduction within 12 months was positively associated with satisfaction regarding efficacy (OR 1.19, 95% CI 1.11 to 1.27) and tolerability (OR 1.11, 95% CI 1.03 to 1.21). CONCLUSION: Most patients were satisfied with their treatment's effectiveness and tolerability after 1 year of treatment. Tapering GCs was positively associated with the improvement of patients' satisfaction.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Schäfer M, Albrecht K, Kekow J, et al. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. RMD Open. 2020. PMID: 33051270. doi:10.1136/rmdopen-2020-001290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。